BOZEMAN, Mont., Dec. 14 /PRNewswire/ -- LigoCyte Pharmaceuticals Inc. announces that Dr. J. Donald deBethizy has joined the company's Board of Directors.
Dr. deBethizy has served as the president, CEO, and member of the board of directors at Targacept since August, 2000 and as president and member of the board since March, 1997. He played a key role in raising $138M in funding for the company's development programs, including the successful completion of their IPO in April, 2006. Dr. deBethizy has over 25 years of experience in research and development, including over 10 years in executive positions in the biopharmaceutical field. He has been certified as a Diplomate of the American Board of Toxicology since 1985 and received his M.S. and Ph.D. degrees from Utah State University in Logan, Utah. He currently has adjunct professor appointments at Wake Forest University and Duke University, both in North Carolina. Dr. deBethizy received the Entrepreneur of the Year, Emerging Companies from Carolinas Ernst & Young in 2002. He also serves as a member of the governing body committee for emerging companies in the international BIO trade organization.
"We are pleased to welcome Don deBethizy to our board," said Donald P. Beeman, LigoCyte's CEO. "His international & biopharmaceutical experience, business leadership and venture capital knowledge will be of particular benefit to LigoCyte as we raise our third round of investment financing and move our Norovirus vaccine into the clinic early next year."
About LigoCyte:
LigoCyte, established in 1998, is breaking new ground in the prevention and treatment of infectious diseases and inflammation. The company has produced a number of novel drug compounds that stimulate or suppress immune responses. LigoCyte is advancing its proprietary products into human clinical testing, positioning the company for continued growth and success in the biotechnology industry. For additional information on LigoCyte, please visit www.ligocyte.com.
Binding Science. Better Medicine.
LigoCyte Pharmaceuticals Inc.CONTACT: Karen Sipes, Ph.D., Director, Marketing & Communications ofLigoCyte Pharmaceuticals, Inc., +1-406-556-9228, karen.sipes@ligocyte.com
Web site: http://www.ligocyte.com/
